CAS number 1378865-93-0, Our 4-methyl-2-(1,1,1-trifluoro-2-dimethyl-2-ethyl)pyridine is carefully synthesized and tested to meet the highest purity and quality standards. It plays a critical role in the synthesis of Alpelisib, a targeted therapy for patients with advanced breast cancer or solid tumors harboring PIK3CA mutations. This Alpelisib intermediate serves as a building block for Alpelisib synthesis, enabling the production of drugs that have shown significant efficacy in clinical trials. The precise chemical structure of our intermediates ensures their compatibility and efficacy during synthesis, contributing to high purity and potency of the final pharmaceutical product. 4-Methyl-2-(1,1,1-trifluoro-2-dimethyl-2-ethyl)pyridine intermediate is a key component in the chemical synthesis of Alpelisib and a key intermediate in the entire production process. With its precise molecular formula and weight, it is designed to meet the stringent requirements of pharmaceutical manufacturing, ensuring consistency and reliability in Alpelisib production.JDK owns the first-class production facilities and Quality management equipments, which assures the stable supply of API intermediates. Professional team assure R&D of the product. Against both, we are searching for CMO & CDMO in domestic and international market.